Cytokinetics Inc., of South San Francisco, shared patient baseline characteristics from its phase III study of tirasemtiv, VITALITY-ALS, and results of an international physician survey on the use of noninvasive ventilation in the treatment of amyotrophic lateral sclerosis (ALS) during the International Symposium on ALS/MND (motor neuron disease) in Dublin.